30-Second Executive Brief
Executive Assessment
Natera functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Steady
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 5
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A global leader in cell-free DNA testing, reporting Q2 2026 revenue of $752.8 million (up 37.7% year-over-year) on approximately 1,043,900 tests processed, with oncology testing volume up 57.2%. Natera launched Zenith Genomics, a next-generation whole-genome sequencing assay for rare disease diagnosis, and expanded its Fetal Focus non-invasive prenatal test to screen for 21 genetic diseases including Gaucher disease, while guiding to $2.85-$2.91 billion in full-year 2026 revenue.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions UBS Group
“total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps”
SEC 8-K exhibit (0001604821-26-000015) · Aug 6, 2026
Federal contract disclosures
Department of Veterans Affairs — $48,000: RENASIGHT TESTING SERVICE AT DURHAM VAMC
USAspending.gov · Jul 30, 2026
Department of Veterans Affairs — $42,000: NEXT GENERATION SEQUENCING AND PERIPHERAL BLOOD CTDNA TESTING SERVICES (RESEARCH)
USAspending.gov · Mar 3, 2025
Department of Veterans Affairs — $40,000: MOLECULAR GENETIC TESTING FOR TRANSPLANT REJECTION DETECTION
USAspending.gov · Sep 1, 2026
Department of Veterans Affairs — $204,350: TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES DATA TRANSFER/ REPORTING
USAspending.gov · Sep 27, 2024
Department of Veterans Affairs — $157,000: NATERA KIDNEY DISEASE GENETIC PANEL TESTING
USAspending.gov · Apr 7, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Natera — Natera reports second quarter 2026 financial resultscompany
- BusinessWire — Natera announces commercial launch of Zenith Genomics for rare disease diagnosiscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Natera — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Oncology testing (up 57.2%) is now growing meaningfully faster than Natera's overall business (37.7%), signaling a real portfolio shift
32% confidenceNatera's Q2 2026 revenue grew 37.7% to $752.8 million with total tests processed up 22.4%, but oncology test volume specifically grew 57.2% -- well above the company average -- while it also launched Zenith Genomics for rare disease diagnosis.
This is InsightNodes' own interpretive read: when a single business line grows meaningfully faster than the overall company average, it becomes a progressively larger share of the revenue mix each quarter, so Natera's identity as primarily a prenatal-testing company is shifting toward oncology testing faster than the headline growth figures alone suggest -- this diversification reduces Natera's dependence on women's-health reimbursement dynamics specifically, but also means the company increasingly competes directly with oncology-diagnostics specialists like Exact Sciences (now part of Abbott) rather than staying in its original prenatal-testing lane.
InsightNodes analysis of Natera Q2 2026 results · Aug 14, 2026
Natera's Timeline
A sourced, dated history of Natera's key moments — founding to present.
Mar 2026 · Launches Zenith Genomics for rare disease diagnosis
Natera announced the commercial launch of Zenith Genomics, its next-generation whole-genome sequencing assay designed to improve detection of rare diseases.
Aug 2026 · Q2 2026 revenue up 37.7% to $752.8 million
Natera reported Q2 2026 revenue of $752.8 million, up 37.7% year-over-year, with oncology test volume up 57.2% and total tests processed up 22.4%.